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Abstract: Mast cells (MCs) play critical roles in allergic and inflammatory reactions and contribute
to multiple pathologies in the skin, in which they show increased numbers, which frequently
correlates with severity. It remains ill-defined how MC accumulation is established by the cutaneous
microenvironment, in part because research on human MCs rarely employs MCs matured in the
tissue, and extrapolations from other MC subsets have limitations, considering the high level of MC
heterogeneity. Thymic stromal lymphopoietin (TSLP)—released by epithelial cells, like keratinocytes,
following disturbed homeostasis and inflammation—has attracted much attention, but its impact on
skin MCs remains undefined, despite the vast expression of the TSLP receptor by these cells. Using
several methods, each detecting a distinct component of the apoptotic process (membrane alterations,
DNA degradation, and caspase-3 activity), our study pinpoints TSLP as a novel survival factor
of dermal MCs. TSLP confers apoptosis resistance via concomitant activation of the TSLP/ signal
transducer and activator of transcription (STAT)-5 / myeloid cell leukemia (Mcl)-1 route and a newly
uncovered TSLP/ c-Jun-N-terminal kinase (JNK)/ B-cell lymphoma (Bcl)-xL axis, as evidenced by
RNA interference and pharmacological inhibition. Our findings highlight the potential contribution
of TSLP to the MC supportive niche of the skin and, vice versa, highlight MCs as crucial responders
to TSLP in the context of TSLP-driven disorders.
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1. Introduction
Mast cells (MCs) are tissue-resident key effector cells of Immunoglobulin E (IgE)-mediated allergic
and inflammatory responses, including common skin disorders, such as atopic dermatitis (AD) and
psoriasis [1–6]. As hematopoietic cells, MCs complete their differentiation into mature subsets only
after arriving in peripheral organs, such as the skin, lung, and gut. The skin is the tissue with the
greatest MC density, even in the steady-state [7], which can further increase in the context of cutaneous
inflammation, a process accompanied by an increased abundance of pro-inflammatory mediators [2,4,8].
MC maintenance under both physiological and pathological conditions requires constant signals from
the micro-environment [9–11]. In the skin, the stem cell factor (SCF)/KIT (CD117) axis is believed
to have a critical impact on MC survival, but other factors are likely to contribute, although their
relevance has remained less defined. In fact, MCs are characterized by excellent survival properties in
their natural skin habitat [12,13]. This property is maintained ex vivo, as skin MCs show remarkable
persistence, even in the absence of SCF. Accordingly, several studies have indicated that the protection
from cell death requires factors other than SCF [14–17].
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Thymic stromal lymphopoietin (TSLP) is mostly expressed by epithelial cells, including
keratinocytes [18–20]. The cytokine has attracted considerable attention, as it is renowned for
its Th2 skewing potential and is implicated in widespread allergic and inflammatory disorders in
the skin and lung [18–21]. As a consequence, TSLP targeting by means of tezepelumab (anti-TSLP
antibody) is in clinical trials for asthma and atopic dermatitis [22,23].
While the responsiveness of MCs to TSLP has been occasionally reported [24–28], it remains to be
established if and how MCs of human skin origin are targeted by TSLP. This is of relevance because
MCs are known for their highly heterogeneous nature [7,29,30], so that their response pattern will
depend on the precise MC subset and location.
Here, we identify TSLP as a pro-survival factor of human skin MCs. We kinetically resolve
the sequence of events underlying TSLP’s antiapoptotic action. Initially, TSLP activates the signal
transducer and activator of transcription (STAT)-5 and c-Jun-N-terminal kinase (JNK), which are both
implicated in survival prolongation. STAT5 acts by enhancing myeloid cell leukemia (Mcl)-1, while
JNK is responsible for B-cell lymphoma (Bcl)-xL upregulation. These two well-known antiapoptotic
Bcl-2 proteins jointly organize the survival of skin MCs.
2. Materials and Methods
2.1. Purification and Culture of Human Skin Mast Cells and Other Skin Cells
MCs were isolated from human foreskins, whereby material from several donors (typically between
2 and 9) was combined for one experiment to achieve the cell numbers required, as described [31–33].
The skin was obtained from circumcisions, with the informed consent of the patients or legal guardians
and approval by the university ethics committee. The experiments were conducted according to
the Declaration of Helsinki Principles. The purification was performed using an optimized and
frequently employed protocol, as described [34,35], with several modifications. Briefly, human skin
was cut into strips and treated with dispase (BD Biosciences, Heidelberg, Germany) at 3.5 U/mL and
4 ◦C overnight. The epidermis was removed, and the dermis was chopped into small pieces and
digested with 1.5 mg/mL collagenase type 1 (Cat.Nr. LS004197; Worthington, Lakewood, NJ, USA),
0.75 mg/mL hyaluronidase type 1-S (Cat.Nr. H3506-5G, Sigma, Deisenhofen, Germany), and DNase I at
10 µg/mL (Roche, Basel, Switzerland) at 37 ◦C in a shaking water bath for 1.15 h. The cells were filtered
from remaining tissue. MC purification was achieved with anti-human c-Kit microbeads and the
auto-magnetic activated cell Sorting (MACS) separation device (both from Miltenyi-Biotec, Bergisch
Gladbach, Germany). MC purity consistently exceeded 98%, as assessed by acidic toluidine-blue
staining (0.1% in 0.5 N HCl) and by KIT/FcεRI double staining [34,36]. Viability by trypan blue
exclusion was >99%.
Skin MCs were used either ex vivo or cultured in Basal Iscove medium, supplemented with 10%
fetal calf serum (FCS, Biochrom), SCF (Peprotech, Rocky Hill, NJ, USA) (at 100 ng/mL), and interleukin
(IL)-4 (Peprotech) (10 ng/mL) [37–39].
Skin fibroblasts and keratinocytes, used as controls, were isolated according to routine
protocols [40,41].
2.2. Cell Treatment
Skin MCs were treated with different concentrations of TSLP (Peprotech) for the indicated times
in minimal medium, consisting of Basal Iscove medium (with stable glutamine; Biochrom, Berlin,
Germany), supplemented with 0.5% bovine serum albumin (BSA) (Serva, Heidelberg, Germany). After
incubation, cells were processed for downstream applications (as described below).
For kinase inhibition studies, cells (at 5 × 105 cells/mL) were pre-incubated for 15 min, with
pimozide (STAT5 inhibitor, 5µM), SCH772984 (extracellular signal–regulated kinases (ERK)1/2 inhibitor,
5 µM) (both from Selleckchem, Houston, TX, USA), SB203580 (p38 inhibitor, 5 µM), or SP600125
(JNK inhibitor, 5 µM) (both from ApexBio, Houston, TX, USA), prior to the addition of TSLP. After
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incubation, cells were processed for downstream applications (see reverse transcription - quantitative
polymerase chain reaction (RT-qPCR), immunoblotting, and analysis of survival).
2.3. Analysis of Survival
MCs (at 5 × 105 cells/mL) were treated with different concentrations of TSLP in minimal medium
for the indicated times and processed for survival detection by different methods, based on our
previously established protocols [14].
For YoProTM-1 staining, cells were incubated with the YoProTM-1 dye (Thermo Fisher Science,
Berlin, Germany) and propidium iodide (PI, BD Biosciences) for 30 min on ice. YoProTM-1 staining
detects membrane porosity and, combined with PI, can serve to distinguish apoptotic cells from viable
and necrotic cells.
Apoptosis detection by annexin V-fluorescein isothiocyanate (FITC)/PI (BD Biosciences) was
performed according to the protocol of the supplier. In brief, cells were stained with annexin V-FITC
and PI in annexin V binding buffer (BD Biosciences) for 20 min at room temperature (RT). Annexin
V-FITC detects the externalization of phosphatidylserine and, combined with PI, can distinguish
apoptotic from viable and necrotic cells.
For YoProTM-1/PI and annexin V-FITC//PI, double-positive cells were considered cells in advanced
apoptosis or necrosis, whereas YoProTM-1- or annexin V-FITC-positive but PI-negative cells were
considered early apoptotic. Double-negativity was indicative of viable cells. YoProTM-1 or annexin
V-FITC positivity was calculated as the sum of the percentages displayed in quadrant (q)1 and q2,
based on the values given in Figure 1b,c and Figure S2, with early-apoptotic, late-apoptotic/necrotic,
PI-single positive necrotic, and viable cells being shown in quadrant (q)1, q2, q3, q4, respectively.
For PI staining, cells were treated with PI (Sigma–Aldrich, Taufkirchen, Germany) for 1 h at
4 ◦C, which was performed to detect the percentage of hypodiploid nuclei corresponding to cells with
fragmented DNA. The cells were measured on a MACS Quant FACS (fluorescence-activated cell sorter)
(Miltenyi Biotec, Bergisch Gladbach, Germany) and analyzed using the FlowJo software (FlowJo LLC,
Ashland, OR, USA).
The caspase-3 activity of MCs was measured using a luminometric assay kit (Caspase-Glo® 3/7;
Promega, Mannheim, Germany), providing a proluminescent caspase-3/7 substrate, which is cleaved
to release luminescence, which was detected by means of a microplate reader (Perkin Elmer, Berlin,
Germany), as described [14].
Prior to perturbation experiments, kinetics series were performed to identify the shortest incubation
period, after which survival promotion by TSLP (by YoProTM-1 and caspase-3) could be unambiguously
detected (not depicted). This served to ensure a predominance of direct effects and limit secondary
effects (potentially resulting from other effects of the inhibitors/knockdown strategies on diverse
cellular pathways). We found this period to be 8 h.
Using this period, the ratio of YoProTM-1 positivity (1) or caspase-3 activity (2) in TSLP-treated
versus untreated MCs was calculated by the following formulas in perturbation experiments. Based
on the values given in Figures 3 and 5a, with early-apoptotic, late-apoptotic/necrotic, PI-single positive
necrotic, and viable cells being found in q1, q2, q3, and q4, respectively, the calculation was as follows:
% Rescue effect of TSLP =
(100× [q1+ q2]untreated
[q1+ q2]treated
) − 100, (1)
(100× RLUuntreated
RLUtreated
) − 100. (2)
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Figure 1. Thymic stromal lymphopoietin (TSLP) counters apoptosis of skin mast cells (MCs) upon 
grow factor (GF) withdrawal. Skin-derived MCs were kept without or with TSLP (at 7.5 ng/mL) in 
serum/GF-free medium. (a) Caspase-3 activity as determined after 24 h by Caspase-Glo® 3/7 assay; 
the results represent the mean ± SEM of six independent experiments. RLU = relative luminescence 
units (×104). (b,c) Percentage of cells with (b) YoProTM-1 positivity (corresponding to the percentage 
of early and late apoptotic/necrotic cells combined) after 24 h or (c) fragmented DNA (propidium 
iodide (PI) staining, corresponding to the percentage of subG1 positive cells) after 48 h. The results 
represent the mean ± SEM of six (YoProTM-1) or four (PI) independent experiments. (d) Representative 
flow cytometry dot plots/histograms of (b) (specified in red is the percentage of early and late 
apoptotic/necrotic cells combined) and (c). The data were analyzed by paired t-test, ** p < 0.01, *** p < 
0.001. q—quadrant. 
3.2. TSLP Triggers Activation of STAT5 and JNK 
Next, we addressed the downstream events triggered by TSLP in skin MCs. This was performed 
by studying the phosphorylation of STAT3, STAT5, and the three MAPKs JNK, ERK1/2, and p38. 
Both JNK and STAT5 were phosphorylated on the respective activatory sites following TSLP 
treatment (Figure 2a,e). This was verified by flow cytometry analysis, where the MFI increased by 
about 10-fold for p-STAT5 (Figure S4a) and by 4-fold for p-JNK (Figure S4b) in TSLP stimulated cells. 
In contrast, STAT3, ERK1/2, and p38 showed no modification (Figure 2a,c,d). Conversely, positive 
controls (MCs stimulated by IL-33/SCF [32] or HMC-1 cells [47]), which were used to confirm the 
quality of the technique, rendered the expected bands for all signaling intermediates (Figure S3). 
Figure 1. Thymic stromal lymphopoietin (TSLP) counters apoptosis of skin mast cells (MCs) upon
grow factor (GF) withdrawal. Skin-derived MCs were kept without or with TSLP (at 7.5 ng/mL) in
serum/GF-free medium. (a) Caspase-3 activity as determined after 24 h by Caspase-Glo® 3/7 assay; the
results represent the mean ± SEM of six independent experiments. RLU = relative luminescence units
(×104). (b,c) Percentage of cells with (b) YoProTM-1 positivity (corresponding to the percentage of early
and late apoptotic/necrotic cells combined) after 24 h or (c) fragmented DNA (propidium iodide (PI)
staining, corresponding to the percentage of subG1 positive cells) after 48 h. The results represent the
mean± SEM of six (YoProTM-1) or four (PI) independent experiments. (d) Representative flow cytometry
dot plots/histograms of (b) (specified in red is the perc ntage of early and late poptotic/necrotic cells
combined) and (c). Th data wer analyzed by paired t-t st, ** p < 0.01, *** p < 0.001. q—quadrant.
2.4. Staining of Intracellular and Extracellular Proteins
For the intracellular staining of signaling intermediates, skin MCs (5 × 105 cells/mL) were deprived
of GF (growth facto s)/serum f r 16 h in minimal medium. After starvation, cell ere incubated
for a further 15 min with TSLP, then fixed with 4% p raformaldehyde (PFA) for 30 min t RT and
permeabilized with 0.1% Saponin for 20 min at 4 ◦C. Cells were stained wi h anti-pSTAT5 or anti-pJNK
primary a tibodies (e ch diluted 1:400, both from Cell Signaling Technologies, Danvers, MA, USA)
(or the respective isotype control) for 30 min on ice, followed by incubation with Phycoerythrin
(PE)-labeled secondary antibodies (Jackson Immunoresearch, Cambridgeshire, UK) for 30 min on ice.
For the detection of the TSLP receptor, flow cytometry was performed according to routine
protocols [42]. Briefly, MCs were blocked for 15 min at 4 ◦C with human AB-serum (derived from
patients with blood group AB) (Biotest, Dreieich, Germany) and incubated with an anti-human
TSLP-Receptor PE-conjugated antibody (Immunotools, Friesoythe, Germany) for 30 min at 4 ◦C.
Cells were measured on a MACS Quant FACS (Miltenyi Biotec) and analyzed using the FlowJo
software (FlowJo LLC). Data were shown as net mean fluorescence intensity (MFI), as calculated by
the following equation:
net MFI = MFItarget −MFIIsotype control. (3)
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2.5. siRNA Transfection
RNA interference in MCs was performed according to a recently established protocol [36], using
the Accell® siRNA transfection technology (GE Healthcare Dharmacon, Lafayette, CO, USA). MCs
were transfected by gene-targeting siRNA or non-targeting siRNA (serving as control). Briefly,
MCs were washed with 1X Accell siRNA medium (supplemented with Non-Essential Amino
Acids and L-Glutamine), plated at 106/mL in Accell siRNA medium, and treated with 1 µM
STAT5-targeting siRNA (E-005169-00-0010), JNK-targeting siRNA (E-003514-00-0010), Mcl-1-targeting
siRNA (E-004501-00-0010), Bcl-xL-targeting siRNA (E-003458-00-0010), or non-targeting siRNA
(D-001910-10-50) for 48 h. After incubation, cells were treated with TSLP for the indicated times and
processed for downstream applications (see RT-qPCR, immunoblotting, and analysis of survival).
2.6. RT-quantitative PCR
Skin MCs (5 × 105 cells/mL) were deprived of GF/serum for 16 h in minimal medium. After
starvation, cells were incubated with TSLP for the indicated time points. RT-qPCR was performed as
described, using primers described therein [14]. Briefly, total RNA was isolated using the Nucleo spin
RNA Kit (Macherey-Nagel, Düren, Germany), and RT-qPCR was carried out with the Light Cycler
(LC) Fast Start DNA Master SYBR® Green kit (Roche Applied-Science, Basel, Switzerland).
The expression levels of the target gene were quantified relative to the expression of the reference
gene Cyclophilin B, using the 2−∆∆CT method. The oligonucleotide primers (TIB Molbiol, Berlin,






Skin MCs (5 × 105 cells/mL) were deprived of GF/serum for 16 h in minimal medium. To study the
phosphorylation of signaling molecules, cells were incubated for a further 30 min with TSLP. As positive
controls, we used a combination of SCF (10 ng/mL) and IL-33 (20 ng/mL) for pERK and pp38, and
human mast cell line (HMC)-1 cells (3 × 105 cells per lane), kindly provided by Dr. J.H. Butterfield [43],
for pSTAT3. To examine Mcl-1 and Bcl-xL protein expression, cells were incubated with (or without)
TSLP for 2 h or 4 h. After incubation, MCs were lysed and separated through 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) [36,39]. The proteins were then transferred to
nitrocellulose membranes. The membranes were blocked with 1X casein blocking buffer (Sigma Aldrich,
St. Louis, MO, USA) and incubated with primary antibodies against Mcl-1, Bcl-xL, phospho/total-ERK,
phospho/total-p38, phospho/total-JNK, phospho/total-STAT3, and phospho/total-STAT5, as well as
ß-actin and Cyclophilin B as loading controls (each diluted 1:1000) (all from Cell Signaling Technologies),
overnight, and subsequently with (1:20,000 diluted) HRP (horseradish peroxidase)-conjugated
secondary antibodies (Merck Millipore, Darmstadt, Germany) for 1.5 h, as described [14,31,32].
Finally, blots were developed, and bands visualized by a chemiluminescence assay (Weststar Ultra 2.0,
Cyanagen, Bologna, Italy), according to the manufacturer’s instructions, and the bands were recorded
using a detector for chemiluminescence (Fusion FX7 Spectra, Vilber Lourmat, Eberhardzell, Germany).
Densitometric measurements were assessed by the software ImageJ (National Institutes of Health,
Bethesda, MD, USA) and arbitrary values were determined by the following equation:
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2.8. Statistical Analysis
Results are reported as mean ± standard error of the mean (SEM). In Figure 1, Figure 3, Figure
S4, Figure S5, Figure 5, and Figure S6d,f,h, the data were statistically analyzed by paired t-test. For
normalized data, the Wilcoxon matched-pairs signed rank test was used (Figure 3). In Figure S2,
Figure 4a,b, and Figure 6a–h, the One-way Anova test with Tukey’s post-test for multiple comparisons
was used. P-values less than 0.05 were considered statistically significant. Data were analyzed with
GraphPad Prism Version 6.01 Software (San Diego, CA, USA).
3. Results
3.1. TSLP Counters Apoptosis of Skin MCs upon Growth Factor Withdrawal
After having confirmed that the TSLP receptor is expressed at mRNA (not shown, see also Motakis
et al. [44]) and protein level (Figure S1), we determined whether TSLP influences skin MC survival. MCs
were treated with TSLP in minimal medium (without GF/serum) and analyzed for signs of apoptosis.
As TSLP at 7.5 ng/mL significantly decreased the percentage of annexin V-positive cells (Figure S2),
we selected this concentration for further experiments. In accordance with recommendations from
the Nomenclature Committee on Cell Death (NCCD) [45], we applied different techniques, each
measuring a certain aspect of the apoptotic process, to confirm the above findings. Caspase-3 activity
declined by 42% when TSLP was added (35000 RLU with TSLP versus 60000 RLU in untreated cells), as
depicted in Figure 1a. The green fluorescent YoProTM-1 dye permeates the slightly porous membrane of
apoptotic cells and thus enables the visualization of phosphatidylserine (P-ser)-independent membrane
alterations indicative of apoptosis. Using this method, TSLP-treated MCs displayed 44% less YoProTM-1
positivity (Figure 1b).
Addressing DNA degradation, a characteristic feature of apoptosis in its later stage [46], we found
that the ratio of cells displaying DNA degradation dropped by more than 50% in the presence of TSLP
(Figure 1c).
Together, TSLP protects human skin MCs from apoptosis, as evidenced by different readouts.
3.2. TSLP Triggers Activation of STAT5 and JNK
Next, we addressed the downstream events triggered by TSLP in skin MCs. This was performed
by studying the phosphorylation of STAT3, STAT5, and the three MAPKs JNK, ERK1/2, and p38. Both
JNK and STAT5 were phosphorylated on the respective activatory sites following TSLP treatment
(Figure 2a,e). This was verified by flow cytometry analysis, where the MFI increased by about 10-fold
for p-STAT5 (Figure S4a) and by 4-fold for p-JNK (Figure S4b) in TSLP stimulated cells. In contrast,
STAT3, ERK1/2, and p38 showed no modification (Figure 2a,c,d). Conversely, positive controls (MCs
stimulated by IL-33/SCF [32] or HMC-1 cells [47]), which were used to confirm the quality of the
technique, rendered the expected bands for all signaling intermediates (Figure S3).
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Figure 2. TSLP triggers the activation of signal transducer and activator of transcription (STAT)-5 and 
c-Jun-N-terminal kinase (JNK). The impact of TSLP treatment (at 7.5 ng/mL) on proximal signaling 
events after 30 min, as assessed by Western blotting using antibodies for (a) phospho (p) extracellular 
signal–regulated kinases (ERK)1/2 (n = 3), (b) pJNK, (c) pp38, (d) pSTAT3, and (e) pSTAT5 (shown 
are representative Western blots out of three independent experiments). The respective total (t) 
protein antibodies served as loading controls. Undetectable signals were negative also in time-course 
experiments. 
3.3. MC Maintenance by TSLP Critically Depends on JNK and STAT5 
Having identified JNK and STAT5 activation by TSLP, we investigated whether the two 
signaling intermediates were involved in survival maintenance. This was accomplished by two 
complementary strategies, namely pharmacological interference and knockdown (KD) of the 
respective component by RNA interference (RNAi). The latter approach revealed that survival 
promotion by TSLP indeed depends on STAT5, as the antiapoptotic effect decreased from 35% 
(control) to 10% after STAT5 KD, as assessed by YoProTM-1 positivity (Figure 3a). The same tendency 
was found for caspase-3 activity (Figure 3a). Targeting JNK expression likewise affected TSLP-
conferred apoptosis resistance, which declined from 35% to 15% (Figure 3b). For KD efficiency see 
Figure S5. Interestingly, the KD of STAT5 had no impact on the baseline survival of MCs in the 
absence of TSLP (Figure S6c), whereas JNK KD slightly increased the amount of YoProTM-1 positive 
cells also without TSLP (Figure S6d). 
Specific inhibitors supported the above findings. Pimozide (STAT5 inhibitor) led to a decrease 
from 34% to 4% (Figure 3c), while SP600125 (JNK inhibitor) diminished TSLP-mediated protection 
from 34% to 5% (Figure 3d). In line with their lacking activation by TSLP (Figure 2a,c), ERK1/2 and 
p38 (inhibited by SCH772984 and SB203580, respectively) were not involved in TSLP fostered 
survival (Figure S7). 
Together, interference with STAT5 and JNK impeded TSLP from exerting its anti-apoptotic 
effect, implying key roles for these components in the antiapoptotic machinery contracted by TSLP. 
Figure 2. TSLP triggers the activation of signal transducer and activator of transcription (STAT)-5
and c-Jun-N-terminal kinase (JNK). The impact of TSLP treatment (at 7.5 ng/mL) on proximal
signaling events after 30 min, as assessed by Western blotting using antibodies for (a) phospho
(p) extracellular signal–regulated kinases (ERK)1/2 (n = 3), (b) pJNK, (c) pp38, (d) pSTAT3, and (e)
pSTAT5 (shown are representative Western blots out of three independent experiments). The respective
total (t) protein antibodies served as loading controls. Undetectable signals were negative also in
time-course experiments.
3.3. MC Maintenance by TSLP Critically Depends on JNK and STAT5
Having identified JNK and STAT5 activation by TSLP, we investigated whether the two signaling
intermediates were involved in survival maintenance. This was accomplished by two complementary
strategies, namely phar acological interference and knockdown (KD) of the respective co ponent
by RNA interference (RNAi). The latter approach revealed that survival promotion by TSLP indeed
depends on STAT5, as the antiapoptotic effect decreased from 35% (control) to 10% after STAT5 KD, as
assessed by YoProTM-1 positivity (Figure 3a). The same tendency was found for caspase-3 activity
(Figure 3a). Targeting JNK expression likewise affected TSLP-conferred apoptosis resistance, which
declined from 35% to 15% (Figure 3b). For KD efficiency see Figure S5. Interestingly, the KD of STAT5
had no impact on the baseline survival of MCs in the absence of TSLP (Figure S6c), whereas JNK KD
slightly increased the amount of YoProTM-1 positive cells also without TSLP (Figure S6d).
Specific inhibitors supported the above findings. Pimozide (STAT5 inhibitor) led to a decrease
from 34% to 4% (Figure 3c), while SP600125 (JNK inhibitor) diminished TSLP-mediated protection
from 34% to 5% (Figure 3d). In line with their lacking activation by TSLP (Figure 2a,c), ERK1/2 and p38
(inhibited by SCH772984 and SB203580, respectively) were not involved in TSLP fostered survival
(Figure S7).
Together, interference with STAT5 and JNK impeded TSLP from exerting its anti-apoptotic effect,
implying key roles for these components in the antiapoptotic machinery contracted by TSLP.
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Figure 3. MC maintenance by TSLP critically depends on JNK and STAT5 activation. Impact of (a,c) 
STAT5 and (b,d) JNK perturbation on TSLP-promoted MC recovery (at 7.5 ng/mL) after 8 h, evaluated 
by the ratio of YoProTM-1 positivity (corresponding to the percentage of early and late 
apoptotic/necrotic cells combined) in TSLP-treated versus untreated MCs (described in methods). 
(a,b) Interference by Accell®-mediated RNAi (48 h prior to TSLP treatment); (c,d) interference by 
specific inhibitors (STAT5 inhibitor: pimozide, JNK inhibitor: SP600125). Top: the results represent 
the mean ± SEM of six independent experiments. Bottom: representative flow cytometry dot plots 
(specified in red is the percentage of early and late apoptotic/necrotic cells combined); w/o—without. 
The data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001. 
Figure 3. MC maintenance by TSLP critically depends on JNK and STAT5 activation. Impact of (a,c)
STAT5 and (b,d) JNK perturbation on TSLP-promoted MC recovery (at 7.5 ng/mL) after 8 h, evaluated
by the ratio of YoProTM-1 positivity (corresponding to the percentage of early and late apoptotic/necrotic
cells combined) in TSLP-treated versus untreated MCs (described in methods). (a,b) Interference by
Accell®-mediated RNAi (48 h prior to TSLP treatment); (c,d) interference by specific inhibitors (STAT5
inhibitor: pimozide, JNK inhibitor: SP600125). Top: the results represent the mean ± SEM of six
independent experiments. Bottom: representative flow cytometry dot plots (specified in red is the
percentage of early and late apoptotic/necrotic cells combined); w/o—without. The data were analyzed
by paired t-test, ** p < 0.01, *** p < 0.001.
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3.4. TSLP up-Regulates Mcl-1 and Bcl-xL
Various pro- and antiapoptotic factors are implicated in the orchestration of cell survival decisions,
among which the Bcl-2 family is typically targeted by GFs. We delineated TSLP-mediated changes in
Bcl-2 family members, finding significant increases in Mcl-1 and Bcl-xL mRNA expression at both 40
and 90 min (Figure 4a,b). In contrast, TSLP treatment did not modulate the expression of Bad, Bax,
Bak, Bid, and Bcl-2 (Figure S8), although there was a slight tendency towards a reduced expression of
proapoptotic Bad and Bax (Figure S8a,b).
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Figure 4. TSLP up-regulates Mcl-1 and Bcl-xL. TSLP-induced expression (at 7.5 ng/mL) was studied by
(a,b) reverse transcription - quantitative polymerase chain reaction (RT-qPCR) analysis of (a) Mcl-1 and
(b) Bcl-xL; normalized to the housekeeping gene Cyclophilin B. The results represent the mean ± SEM
of nine independent experiments. The data were analyzed by the one-way Anova test with Tukey’s
post-test for multiple comparisons, comparing each treatment (40′ or 90′) with the respective control
group; * p < 0.05, ** p < 0.01; and (c,d) Western blot analysis using the indicated antibodies (shown are
representative Western blots out of three independent experiments); the anti-β-Actin antibody served
as loading control. Densitometry arbitrary units were normalized to the housekeeping protein.
Increased Mcl-1 and Bcl-xL expression was verified by Western blot, whereby Bcl-xL expression,
and even more so Mcl-1 expression, were remarkably increased by TSLP, especially at the 2 h time
point (Figure 4c,d).
3.5. Survival by TSLP Depends on Mcl-1 and Bcl-xL
As the above results suggested a role for Mcl-1, Bcl-xL or bot in sur ival promotion by TSLP, we
employed an RNAi approach to experimentally prove this connection.
MC rescue by TSLP reached 16% using control siRNA, while the value qually dropped to 6%
when cl-1- or Bcl-xL-targeting siRNA were used, as determin d y caspase-3 activity (Figure 5b).
This was verified by YoProTM-1, whereby the protective effect of TSLP ropp d from 30% (control) to
8% (Mcl-1-silencing) or 9% (Bcl-xL-silencing) (Figure 5a). In the absence of TSLP, we observed that the
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KD of Mcl-1 did not affect MC recovery (Figure S6a), while the deficiency of Bcl-xL resulted in slightly
reduced survival (Figure S6b). Taken together, both Mcl-1- and Bcl-xL contribute comparably to the
survival promotion conferred by TSLP.
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Figure 5. Survival prolongation by TSLP depends on Mcl-1 and Bcl-xL. Impact of Mcl-1 and Bcl-xL
knockdown on TSLP-promoted MC recovery (at 7.5 ng/mL), as evaluated by apoptosis reduction in
TSLP-treated versus untreated MCs after 8 h. (a) Reduction of YoProTM-1-positivity (corresponding to
the percentage of early and late apoptotic/necrotic cells combined) as mean ± SEM of nine independent
experiments (left) and representative flow cytometry dot plots (right) (specified in red is the percentage
of early and late apoptotic/necrotic cells combined); w/o—without; (b) reduction of caspase-3 activity
as mean ± SEM of nine independent experiments. The data were analyzed by paired t-test, ** p < 0.01,
*** p < 0.001.
3.6. STAT5 Perturbation Leads to Mcl-1 Downregulation, While Interference with JNK Attenuates
Bcl-xL Expression
Our above findings demonstrated that STAT5 and JNK, as well as Mcl-1 and Bcl-xL, are required
for surviv l prolo gation by TSLP. W were finally interested in unraveling the relationships b twe n
the early and the later events. To this end, the TSLP modula ion of Mcl-1 and Bcl-xL evels was
monitored upon interference with STAT5 and JNK function. While STAT5 perturbation comp tely
blocked Mcl-1 upregulation by TSLP (Figure 6a,b), the level of Bcl-xL was not affected by this treatment
(Figure 6c,d). Again, the o tcomes between TAT5-RNAi and t e STAT5 inhibitor were consistent.
Conversely, i erference with the JNK function rev rsed TSLP’s effect on Bcl-xL expression (Figure 6g,h),
hereas Mcl-1 remai ed unaffected (Figure 6e,f). The nullified effect regarding Bcl-xL xpression was
consistent between RNAi and JNK inhibition. A clear distinction between th two antiapoptotic Bcl-2
members was confirm d at the protei level (Figur 6i,j). Conversely, the mRNA expression of Bax and
Bid, studied for c ntrol pur ses, was not affected by STAT5 or JNK int rfe ence (Figure S9a–h). We
conclude that apoptosis resistance by TSLP results from the concomitant activation of a STAT5/Mcl-1
and a JNK/Bcl-xL axis.
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(at 7.5 ng/mL) f (a,b,e,f) Mcl-1 n (c,d,g,h) Bcl-xL after 40 min, using (a,c,e,g) knockdown by RNAi
(48 h prior to the experiment) and (b,d,f,h) pre-incubation with specific inh bitors (STAT5 inhibitor:
pimozide, JNK inhibit r: SP600125), evaluated by RT-qPCR analys s (normalized to Cyclophilin B). The
results represent th mean ± SEM f five (RNAi) or six (inhibitors) independent experiments. Th data
were analyzed by th one-way Anova t st with Tukey’s post-test for multiple compa isons, * p < 0.05,
** < 0.01; (i,j) impact of specific inhibitors on the TSLP modulation of (i) Mcl-1 and (j) Bcl-xL by
Western blot analysis (shown are representative Western blots out of two independent experiments).
De sitometry units were normalized to the housekeeping protein.
3.7. TSLP Protects Skin MCs Ex Vivo from Cell Death
It was importa t to assess whether TSLP protects against MC apoptosis directly upon their
isolation from skin tissue. In fact, several differences exist between skin MCs ex vivo and upon
long-term pre-culture [38,44,48]. This also applies to the cells’ baseline survival, whereby ex vivo MCs
display robust survival, even in the absence of exogenous GFs [14]. We treated skin-derived MCs
immediately after purification with different concentrations of TSLP (in GF-/serum-free medium) and
found full protection at the low concentration of 0.35 ng/mL (data not shown). To find the reason behind
this exquisite sensitivity, we assessed TSLP receptor (TSLPR) expression by FACS and found robust
staining in ex vivo MCs (Figure 7a), in accordance with the FANTOM5 atlas, where ex vivo skin MCs
cells displayed the highest levels of the transcript across nearly 1800 samples (gene: CRLF2) [44,49].
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Figure 7. (a) Representative flow cytometry histogram of TSLP receptor (TSLPR) surface expression
on skin MCs ex vivo (one representative out of four independent stainings is depicted); blue: Isotype
control; red: anti-TSLPR. (b–d) TSLP counters apoptosis of skin MCs ex vivo. Freshly isolated skin
MCs were kept without or with TSLP (at 0.35 ng/mL) in serum/GF-free medium. (b) Caspase-3 activity
as determined after 24 h by Caspase-Glo® 3/7 assay; the results represent the mean ± SEM of six
independent experiments. RLU = relative luminescence units (×103). (c,d) percentage of cells with
(c) YoProTM-1 positivity (corresponding to the percentage of early and late apoptotic/necrotic cells
combined) after 48 h or (d) fragmented DNA (PI staining, corresponding to the percentage of subG1
positive cells) after 48 h. The results represent the mean ± SEM of five independent experiments. The
data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001.
We then confirmed that TSLP interferes with the cell death of ex vivo MCs. All apoptosis detection
techniques applied (in analogy to 3.1) yielded congruent results, i.e., caspase-3 activity (very low in
ex vivo MCs) was attenuated (Figure 7b), and so were the proportions of YoProTM-1-positive cells
(Figure 7c) and sub-G1 nuclei (Figure 7d). Considering the altered survival properties of ex vivo skin
MCs, including their lower proneness to undergo cell death [14,38], the finding that low concentrations
of TSLP can have a survival-favoring effect on these cells is notable and can potentially explain MC
accumulation in the skin in TSLP-rich surroundings.
4. Discussion
Chro ic inflammation is typically associated with increase numbers of MCs in the respective
tissues, where the cells are believed to contribute to the underlying disease [1,2,4,50]. Therefore, there is
strong interest in the mecha isms that govern MC death versus survival decisions, and MC apoptosis
has been proposed as a viable means of limiting the aberrant MC function in allergic and chronic
inflammation [9,51]. To be able to use this arma entarium in a targeted man er, it is essential to
understand the mechanisms by which pathologic MC accumulation is brought about.
Here, we identified a new survival promoter of human skin MCs and revealed the mechanisms of
its action. TSLP operates by the initial activatio of STAT5 and JNK, which subseque tly leads to Mcl-1
and Bcl-xL u regulatio , whose joint action finally impedes skin MC demise. Our results highlight the
parallel existence of a STAT5–Mcl-1 and a JNK–Bcl-xL axis in human skin MCs.
Together with IL-33, TSLP thus represents the second factor derived from resident skin cells (such
as kerati ocytes and fibroblasts [52,53]) to mediate the survival promotion of skin MCs in the absence
of SCF [32]. Both cytokines may therefore orchestrate the numerical MC increase in the inflammatory
micromilieu of skin dis rders. It remains to be seen whether the two factors can further synergize
with each other, or rather, display antagonistic actions in skin MCs. Of interest, IL-33 and TSLP
overlap regarding JNK activation, while IL-33 lacks STAT5-inducing activity, but is highly efficient
at p38 activation [31,32]. One may speculate that the antiapoptotic effect of TSLP is mediated by the
induction of other MC-protective GFs, such as SCF or the presently mentioned IL-33. However, this is
unlikely for several reasons. First, because of the rapidness of the effect, whereby Mcl-1 and Bcl-xL
were upregulated already at 40 min (Figure 4). Second, skin-derived MCs are poor producers of SCF
and IL-33, as compared to other skin-resident cells, such as keratinocytes and fibroblasts (Figure S10),
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and this is perfectly in accordance with the FANTOM5 atlas, where both GFs were undetectable in the
majority of MC samples [44]. Treating our MCs with TSLP did not change this picture, and the mRNA
levels of SCF and IL-33 remained unaffected and low (Figure S10). The antiapoptotic effect of TSLP
was therefore likely direct without detour via another GF.
TSLP notably contributes to skin disorders like AD [20,54], and accordingly, binding to its specific
receptor has been reported to regulate selected aspects of MC biology, including maturation and
mediator secretion [24–27]. In this regard, Lai et al. demonstrated that TSLP can increase Tryptase
storage [55], whereas Rönnberg et al. showed an opposite effect [28], underlining the heterogeneous
character of MCs. Han et al. described an antiapoptotic effect in the human MC line (HMC)-1 (as
well as in the immature murine bone marrow-derived mast cell (BMMC) [27], while human lung
MCs did not experience survival promotion by TSLP [25]. Together, this indicates that immaturity
and/or malignant transformation may have pre-disposed to survival rescue by TSLP, which is also
in accordance with a recent finding of increased TSLPR expression in the continuously growing MC
line ROSA vis-à-vis primary MCs [28]. However, because skin MCs, not studied previously, represent
primary, fully differentiated MCs, just like lung MCs, our current data instead imply that MCs at a
post-maturation stage are amenable to survival protection by TSLP and that the microenvironment in
which they completed maturation will primarily dictate this response. Because skin MCs are of the
so-called MCTC subset, whereas most MCs in the lung are of the MCT type [29,30], the current results
may also suggest a dichotomy between MCTC and MCT MCs in their response pattern to TSLP. The
TSLP/TSLPR axis has been indicated to strengthen the MC compartment also in vivo in humans and
mice [27,55].
Our findings with freshly isolated dermal MCs (Figure 7) strengthen the assumption that MCs
are protected by TSLP in the skin habitat. In fact, the cytokine considerably reduces apoptosis in
this physiological MC subtype, despite the low proneness of these cells to undergo cell death, even
under harsh conditions. Interestingly, TSLP is efficient at low concentrations, i.e., within the range
produced by primary keratinocytes [41], which is likely related to the cells’ intense expression of
TSLPR (Figure 7a). Although inter-cell comparisons based on FACS measurements may be somewhat
problematic, tendencies can be inferred, at least for the percentages of receptor-positive cells. This
limitation in mind, ex vivo skin MCs seem to express TSLPR at higher levels compared to cultured
skin MCs (see Figure 7a versus Figure S1) and in comparison to primary lung-derived MCs [28]. The
difference at mRNA level (ex vivo versus cultured) is, moreover, in accordance with the FANTOM5
atlas [44,49]. Of note, the protective effect of TSLP in ex vivo MCs was in a similar range as the one
afforded by SCF in these cells [14]. Therefore, both cultured and ex vivo skin MCs respond similarly to
TSLP with regard to survival promotion. Since cultured MCs depend more strongly on exogenous GFs
and are overall more prone to die, these cells were more adequate to study the molecular underpinnings
behind TSLP’s protection.
Addressing the mechanisms, we first found that STAT5 and JNK are both phosphorylated
and implicated in TSLP-conferred apoptosis resistance, as their ablation or inhibition impaired
survival promotion.
Although TSLP can trigger disparate signal transduction pathways, depending on the cell
type [56], the activation of STAT5 represents the canonical and best documented pathway in a number
of cells [57–63]. Its activation in MCs was therefore plausible, although this had not been addressed
by previous studies. Surprisingly, STAT5 activation was complemented by JNK, which proved to
be a further effector pathway organizing MC survival, as its inhibition or KD abolished TSLP’s
survival-promotion. In contrast to STAT5, JNK has, to our knowledge, only been reported as being
triggered by TSLP in stromal, but not in hematopoietic cells [64].
Our finding that STAT5 contributes to TSLP’s survival machinery in skin MCs is consistent with
a long series of studies, demonstrating its relevance in the MC lineage [65–70]. In fact, STAT5 can
contribute to the expression of antiapoptotic Bcl-2 members in MCs, even if not specifically Mcl-1, but
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this distinction may stem from the different MC subsets used in their (murine BMMCs) [65] vis-à-vis
our study.
In contrast, JNK is described as a “double-edged sword”, either promoting or inhibiting apoptosis,
depending on the precise conditions [71,72]. In skin MCs a survival-prolonging effect seems to prevail,
as observed for TSLP treated MCs but also somewhat at baseline, as interference with JNK acted in a
proapoptotic manner under both conditions (Figure 3b,d, Figure S6d,h). This is in accordance with a
previous report showing that survival promotion by KIT occurs in a JNK-dependent manner in HMC-1
cells [73].
We then addressed the potential downstream targets of STAT5 and JNK. The Bcl-2 family,
comprising antiapoptotic members like Bcl-2, Bcl-xL, Mcl-1, and proapoptotic entities, including Bad,
Bax, Bak, and Bid, crucially controls the mitochondrial pathway of apoptosis. Their participation in
the regulation of MC survival has been described in multiple reports [14,74–76].
We found that Bcl-xL and Mcl-1 were distinctively upregulated by TSLP. To clarify their individual
roles in survival promotion, we employed RNA interference to deplete Mcl-1 and Bcl-xL expression
prior to stimulation with TSLP. Interestingly, Mcl-1 and Bcl-xL both equally imparted TSLP protection.
This is in line with previous reports demonstrating that Mcl-1 is tightly connected to death/survival
decisions of the lineage in transgenic mice [77], and in MCs of murine [78] and human origin [14,76,79].
In fact, we recently identified Mcl-1 as the main contributor to the longevity of human skin MCs [14], a
function supported by the vast expression of Mcl-1 in ex vivo skin MCs [44]. Upon culture, the levels of
Mcl-1 decline, and this reduced expression is insufficient to maintain survival unless further supported
by GFs. Consistently, we found here that the KD of Mcl-1 did not impair baseline survival, suggesting
that Mcl-1 is required to execute the protective function of TSLP, whereas it does not seem crucial for
survival control in its absence.
KD experiments identified Bcl-xL as another factor controlling MC survival in the presence of
TSLP. This antiapoptotic molecule has likewise been widely documented as a survival promoter of MCs,
however primarily in response to IL-33, SCF, and IgE receptor activation [16,74–76]. Conversely, its
involvement in TSLP-mediated responses was unexpected and represents a novel finding of this study.
After revealing the crucial roles of Mcl-1 and Bcl-xL, we sought to examine potential links between
the proximal events (STAT5 and JNK activation) and the subsequent upregulation of these factors.
Intriguingly, we found a clear-cut distinction between the Bcl-2 family members, as inhibition of
STAT5 counteracted Mcl-1 with no impact on Bcl-xL expression, whereas JNK perturbation resulted in
decreased Bcl-xL upregulation without affecting Mcl-1 expression, speaking in favor of well separated
pathways. In fact, Mcl-1 can be activated by STAT5 and regulate survival in different cells [80–82].
Because Bcl-xL has also been reported as a target of STAT5 in other cell types [83,84], the precise
disconnection in the transcriptional prerequisites uncovered here was unexpected. In fact, Bcl-xL was
even found to be under negative influence from JNK in a number of other cells [85,86].
We assume that the simultaneous upregulation of both factors is necessary to exceed a certain
“antiapoptotic” threshold to allow for TSLP’s protective function to come into force. In this scenario,
TSLP would only counteract cell death in the event of both antiapoptotic Bcl-2 members jointly reaching
this point. This theory is supported by findings showing that mitochondrial membrane disruption
and concomitant cytochrome c release can depend on a distinct threshold of mitochondrial membrane
permeabilization [87].
5. Conclusions
Taken together, we uncovered TSLP as a novel survival factor of human skin MCs, which exerts
its antiapoptotic effect by the synchronized activation of STAT5 and JNK, the ensuing segregated
upregulation of Mcl-1 and Bcl-xL, and consequent apoptosis resistance. The increased lifespan is
thus owed to the concomitant activation of two axes, namely STAT5/Mcl-1 and JNK/Bcl-xL. Our
findings support a role for TSLP as a crucial component of the MC supportive niche in lesional
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skin, and its overabundance during disturbed homeostasis may help explain MC accumulation in
cutaneous pathology.
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